Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Stopping HIV Meds May Double the Rate of Liver Fibrosis in Co-Infected

May 9, 2011

From a study reported in the April 24, 2011 issue of AIDS, people co-infected with HIV and hepatitis C who stop taking their HIV meds run about a 2.5 times higher risk of liver fibrosis compared to those who don't interrupt their HIV regimens. This finding echoes similar results from other studies such as SMART in HIV mono-infected individuals, which showed that interrupting HIV treatment increases the risk of certain non-AIDS conditions.

Advertisement

The CTN222 study followed 541 co-infected people who had stopped HIV meds for at least two weeks. Only those who had little or no fibrosis were included and followed for an average of one year. Fibrosis was measured every six months by using blood markers, called the APRI method. Significant fibrosis was considered as an APRI score of 1.5 or more. (Ultrasounds or biopsies were not done, which are considered more accurate tests for fibrosis.)

Over six years of study, a total of 53 people stopped their HIV meds for an average of 180 days. A partially different group of 53 people developed significant fibrosis. Although lower CD4 counts and detectable viral loads partly contributed to the higher risk of fibrosis, stopping HIV meds appears to independently increase the risk as well.

These results underscore the need for careful choices of appropriate HIV regimens and follow-up of a patient's health to limit treatment interruptions. They further emphasize the need for staying on an HIV regimen during HCV treatment, which can be difficult given the dearth of information from few drug interactions studies between the full range of HIV meds and the two recently approved hepatitis C drugs, Incivek (telaprevir) and Victrelis (boceprevir).


Research Study

Thorpe, J; et al. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. April 24, 2011 issue of AIDS.



  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Project Inform. Visit Project Inform's website to find out more about their activities, publications and services.
 
See Also
More on Medication-Related Liver Problems

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement